Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Varian Medical Systems (VAR) USD (CDI)

Sell:$148.87 Buy:$148.88 Change: $0.25 (0.17%)
Market closed |  Prices as at close on 17 January 2020 | Switch to live prices |
Change: $0.25 (0.17%)
Market closed |  Prices as at close on 17 January 2020 | Switch to live prices |
Change: $0.25 (0.17%)
Market closed |  Prices as at close on 17 January 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Varian Medical Systems, Inc. is a manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, cardiac radioablation, radiosurgery, proton therapy and brachytherapy. The Company also has Varian Particle Therapy (VPT) and the operations of the Ginzton Technology Center (GTC). Its VPT business develops, designs, manufactures, sells and services products and systems for delivering proton therapy, another form of external beam radiotherapy using proton beams for the treatment of cancer. Its ProBeam system is capable of delivering intensity modulated proton therapy (IMPT) using pencil beam scanning technology. Its ProBeam Compact is a single room proton therapy product. Through its subsidiary, Cooperative CL Enterprises, the Company distributes radiotherapy equipments in Taiwan.

Contact details

3100 Hansen Way Bldg 4A
United States
+1 (650) 4934000

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$13.55 billion
Shares in issue:
90.91 million
Health Care Equipment
New York Stock Exchange
United States
US dollar

Key personnel

  • R. Andrew Eckert
    Independent Chairman of the Board
  • Dow Wilson
    President, Chief Executive Officer, Director
  • Gary Bischoping
    President - Interventional Solutions
  • Timothy Guertin
    Independent Vice Chairman of the board
  • J. Michael Bruff
    Chief Financial Officer, Senior Vice President - Finance
  • Chris Toth
    President - Oncology Systems
  • Kolleen Kennedy
    President - Proton Solutions Division and Chief Growth Officer
  • John Kuo
    Senior Vice President, General Counsel, Corporate Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.